PCRX · Pacira Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $177.38M | - | $179.52M | $181.10M | $168.92M | - | $168.57M | $178.02M | $167.12M | - |
| Cost of Revenue | $36.41M | - | $34.28M | $40.87M | $34.31M | - | $38.86M | $44.26M | $47.42M | - |
| Gross Profit | $140.96M | - | $145.24M | $140.23M | $134.62M | - | $129.71M | $133.76M | $119.70M | - |
| R&D | $28.07M | - | $25.97M | $28.20M | $25.34M | - | $19.10M | $20.34M | $18.24M | - |
| SG&A | $93.94M | - | $91.80M | $88.58M | $86.78M | - | $74.33M | $68.13M | $72.03M | - |
| Total Operating Expenses | $170.47M | - | $173.15M | $172.60M | $166.93M | - | $308.10M | $149.78M | $153.91M | - |
| D&A | $21.33M | - | $6.90M | $13.00M | $21.17M | - | $6.00M | $4.50M | $18.43M | - |
| Operating Income | $6.90M | - | $6.36M | $8.50M | $1.99M | - | ($139.53M) | $28.24M | $13.21M | - |
| Interest Expense | $3.70M | - | $4.28M | $4.70M | $3.32M | - | $4.69M | $3.88M | $3.32M | - |
| Income Tax | $2.08M | - | $4.09M | $2.92M | $3.89M | - | $4.61M | $17.70M | $4.66M | - |
| Net Income | $2.92M | - | $5.43M | ($4.85M) | $4.81M | - | ($143.47M) | $18.89M | $8.98M | - |
| EPS - Basic | $0.07 | - | $0.12 | ($0.11) | $0.10 | - | ($3.11) | $0.41 | $0.19 | - |
| EPS - Diluted | $0.07 | - | $0.12 | ($0.11) | $0.10 | - | ($3.11) | $0.39 | $0.19 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144.31M | $158.54M | $147.59M | $300.48M | $283.61M | $276.77M | $245.97M | $247.05M | $184.05M | $153.30M |
| Accounts Receivable | $125.64M | $124.07M | $115.27M | $114.37M | $104.75M | $113.30M | $100.65M | $104.78M | $101.64M | $105.56M |
| Inventory | $150.37M | $152.86M | $157.68M | $148.16M | $133.75M | $125.28M | $111.86M | $103.44M | $96.78M | $104.35M |
| Accounts Payable | $14.01M | $15.15M | $17.69M | $30.12M | $23.17M | $19.13M | $19.37M | $18.73M | $8.98M | $15.70M |
| Current Assets | $514.96M | $547.97M | $562.75M | $745.61M | $759.96M | $745.13M | $689.97M | $632.21M | $543.11M | $509.99M |
| Total Assets | $1.21B | $1.26B | $1.30B | $1.54B | $1.59B | $1.55B | $1.52B | $1.65B | $1.58B | $1.57B |
| Current Liabilities | $108.79M | $120.59M | $107.08M | $313.16M | $314.73M | $309.92M | $306.40M | $92.69M | $93.44M | $97.38M |
| Long-term Debt | $367.66M | $372.19M | $376.72M | $580.49M | $583.38M | $585.32M | - | - | - | $522.44M |
| Total Liabilities | $554.64M | $571.81M | $570.36M | $779.50M | $788.13M | $775.17M | $772.11M | $767.54M | $691.16M | $704.26M |
| Stockholders' Equity | $653.89M | $693.11M | $727.21M | $757.77M | $798.54M | $778.35M | $749.58M | $879.28M | $892.16M | $870.13M |
| Retained Earnings | ($196.41M) | ($199.32M) | ($200.96M) | ($206.39M) | ($201.54M) | ($206.36M) | ($222.40M) | ($78.93M) | ($97.82M) | ($106.80M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $25.68M | - | - | - | $35.46M | - | - | - | $49.10M | - |
| Investing Cash Flow | $19.44M | - | - | - | ($25.63M) | - | - | - | ($15.53M) | - |
| Financing Cash Flow | ($59.40M) | - | - | - | ($2.99M) | - | - | - | ($2.82M) | - |
| CapEx | $2.72M | - | - | - | $8.55M | - | - | - | $2.84M | - |
| Free Cash Flow | $22.96M | - | - | - | $26.91M | - | - | - | $46.27M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 79.5% | - | 80.9% | 77.4% | 79.7% | - | 76.9% | 75.1% | 71.6% | - |
| Operating margin | 3.9% | - | 3.5% | 4.7% | 1.2% | - | -82.8% | 15.9% | 7.9% | - |
| EBITDA margin | 15.9% | - | 7.4% | 11.9% | 13.7% | - | -79.2% | 18.4% | 18.9% | - |
| Net margin | 1.6% | - | 3.0% | -2.7% | 2.8% | - | -85.1% | 10.6% | 5.4% | - |
| Free cash flow margin | 12.9% | - | - | - | 15.9% | - | - | - | 27.7% | - |
| FCF / Net income | 7.87 | - | - | - | 5.59 | - | - | - | 5.15 | - |
| R&D / Revenue | 15.8% | - | 14.5% | 15.6% | 15.0% | - | 11.3% | 11.4% | 10.9% | - |
| SG&A / Revenue | 53.0% | - | 51.1% | 48.9% | 51.4% | - | 44.1% | 38.3% | 43.1% | - |
| Effective tax rate | 41.7% | - | 43.0% | - | 44.7% | - | - | 48.4% | 34.2% | - |
| Return on assets | 0.2% | - | 0.4% | -0.3% | 0.3% | - | -9.4% | 1.1% | 0.6% | - |
| Return on equity | 0.4% | - | 0.7% | -0.6% | 0.6% | - | -19.1% | 2.1% | 1.0% | - |
| Return on invested capital | 0.4% | - | 0.3% | 0.5% | 0.1% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.73 | 4.54 | 5.26 | 2.38 | 2.41 | 2.40 | 2.25 | 6.82 | 5.81 | 5.24 |
| Quick ratio | 3.35 | 3.28 | 3.78 | 1.91 | 1.99 | 2.00 | 1.89 | 5.70 | 4.78 | 4.17 |
| Cash ratio | 1.33 | 1.31 | 1.38 | 0.96 | 0.90 | 0.89 | 0.80 | 2.67 | 1.97 | 1.57 |
| Leverage | ||||||||||
| Debt / Equity | 0.56 | 0.54 | 0.52 | 0.77 | 0.73 | 0.75 | - | - | - | 0.60 |
| Debt / Assets | 0.30 | 0.29 | 0.29 | 0.38 | 0.37 | 0.38 | - | - | - | 0.33 |
| Debt / EBITDA | 13.02 | - | 28.41 | 27.00 | 25.19 | - | - | - | - | - |
| Interest coverage | 1.9x | - | 1.5x | 1.8x | 0.6x | - | -29.8x | 7.3x | 4.0x | - |
| Equity multiplier | 1.85 | 1.82 | 1.78 | 2.03 | 1.99 | 2.00 | 2.03 | 1.87 | 1.77 | 1.81 |
| Liabilities / Assets | 0.46 | 0.45 | 0.44 | 0.51 | 0.50 | 0.50 | 0.51 | 0.47 | 0.44 | 0.45 |
| Efficiency | ||||||||||
| Asset turnover | 0.15 | - | 0.14 | 0.12 | 0.11 | - | 0.11 | 0.11 | 0.11 | - |
| Inventory turnover | 0.24 | - | 0.22 | 0.28 | 0.26 | - | 0.35 | 0.43 | 0.49 | - |
| Days sales outstanding | 259d | - | 234d | 231d | 226d | - | 218d | 215d | 222d | - |
| Days inventory outstanding | 1507d | - | 1679d | 1323d | 1423d | - | 1051d | 853d | 745d | - |
| Days payable outstanding | 140d | - | 188d | 269d | 247d | - | 182d | 154d | 69d | - |
| Cash conversion cycle | 1625d | - | 1725d | 1285d | 1403d | - | 1087d | 913d | 898d | - |
| Valuation | ||||||||||
| P / E | 322.9x | - | 214.8x | - | 248.5x | - | - | 73.4x | 153.8x | - |
| P / B | 1.4x | - | 1.6x | 1.4x | 1.4x | - | 0.9x | 1.6x | 1.7x | - |
| P / S | 5.2x | - | 6.4x | 6.0x | 6.8x | - | 4.1x | 8.1x | 9.1x | - |
| EV / EBITDA | 40.7x | - | 103.7x | 63.6x | 62.9x | - | - | 36.6x | 42.4x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 5.0% | - | 6.5% | 1.7% | 1.1% | - | 2.8% | 5.0% | 4.2% | - |
| Revenue CAGR (3y) | 3.4% | - | 2.3% | 2.2% | 2.3% | - | 9.7% | 9.5% | 12.0% | - |
| Revenue CAGR (5y) | 8.3% | - | 9.0% | 19.2% | 10.0% | - | 10.0% | 11.7% | 12.8% | - |
| Gross profit growth (YoY) | 4.7% | - | 12.0% | 4.8% | 12.5% | - | 4.5% | 10.3% | 7.5% | - |
| Operating income growth (YoY) | 246.8% | - | - | -69.9% | -84.9% | - | - | -29.2% | - | - |
| Net income growth (YoY) | -39.4% | - | - | - | -46.4% | - | - | -26.7% | - | - |
| EPS growth (YoY) | -30.0% | - | - | - | -47.4% | - | - | -23.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | -12.6% | - | - | -2.4% | -6.2% | - |
| EPS CAGR (5y) | -21.2% | - | -47.3% | - | - | - | - | 45.4% | - | - |
| FCF growth (YoY) | -14.7% | - | - | - | -41.8% | - | - | - | 268.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | 99.0% | - |
| Book value growth (YoY) | -18.1% | -11.0% | -3.0% | -13.8% | -10.5% | -10.5% | -9.9% | 8.8% | 16.2% | 12.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$726.41M totalReportable Segment$726.41M · 100.0%
Product / service
$1.45B totalProduct$722.85M · 49.9%
EXPAREL$575.13M · 39.7%
ZILRETTA$116.63M · 8.0%
Iovera$24.18M · 1.7%
Bupivacaine Liposome Injectable Suspension$6.91M · 0.5%
Royalty$3.56M · 0.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Pacira BioSciences against the 5 most active filers in the same SIC group.